<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017665</url>
  </required_header>
  <id_info>
    <org_study_id>2013/374/E</org_study_id>
    <nct_id>NCT02017665</nct_id>
  </id_info>
  <brief_title>Singapore Neurologic Infections Program</brief_title>
  <acronym>SNIP</acronym>
  <official_title>Singapore Neurologic Infections Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Khoo Teck Puat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Health System, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, central nervous system infections such as inflammation of brain (encephalitis),&#xD;
      inflammation of meninges (meningitis) and sudden onset of weakness of muscles which maybe&#xD;
      infectious in origin result in significant illness and death and healthcare costs. Vast&#xD;
      majority of central nervous system infections remain without an identifiable cause. There is&#xD;
      also concern about new and emerging infections.&#xD;
&#xD;
      This study thus intends to fill in the gaps in knowledge with regards to central nervous&#xD;
      system infections in Singapore to give a thorough description of burden of causes of central&#xD;
      nervous system infections and detection of outbreaks of new pathogens. Patients suspected of&#xD;
      central nervous system infection will be recruited from 5 restructured Singapore hospitals&#xD;
      and their blood and other clinical specimens will be sent for testing. Patients will also be&#xD;
      followed up to assess long term outcomes and socio-economic costs of these infections. This&#xD;
      will help clinicians, policymakers and public health officials in estimating financial and&#xD;
      societal costs of CNs infections in Singapore.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to:&#xD;
&#xD;
        1. To describe the epidemiology of CNS infections in Singapore.&#xD;
&#xD;
        2. To improve the diagnosis of aetiologies of CNS infections through a systematic clinical,&#xD;
           laboratory and neuro-radiological evaluation and extensive diagnostic testing.&#xD;
&#xD;
        3. To evaluate the prognosis, long-term outcomes and socio-economic costs of CNS&#xD;
           infections.&#xD;
&#xD;
        4. To establish an archive of biological tissues from patients with encephalitis and CNS&#xD;
           infections that can be utilized for future testing for emerging novel pathogens or&#xD;
           non-infectious aetiologies.&#xD;
&#xD;
      The study will recruit 400 patients over 2 years from 5 restructured hospitals in Singapore.&#xD;
      As this is not a comparative study, sample size was not determined.&#xD;
&#xD;
      The study involves clinical and laboratory data collection. Data will also be collected on&#xD;
      quality of life and for health economic analysis. The quality of data and its integrity will&#xD;
      be periodically reviewed by the Principal Investigator and members of the study team. All&#xD;
      samples stored will be de-identified and all data will be de-identified during analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Incidence rate of the various infective etiologies causing CNS infections in Singapore</measure>
    <time_frame>36 months</time_frame>
    <description>Annual rates of the various infective causes from year 2013 to year 2016</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical features of patients with CNS infections in Singapore</measure>
    <time_frame>Between D1(day of recruitment)-D180(last day of follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical characteristics of patients diagnosed with CNS infections: .</measure>
    <time_frame>Day1- Day180</time_frame>
    <description>gender, presenting symptoms, duration between symptoms to diagnosis etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical course of patients with CNS infections,</measure>
    <time_frame>Day1-Day180</time_frame>
    <description>development of any complications and their long term outcomes/prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment modalities of the CNS infections</measure>
    <time_frame>Day 1-Day 180</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Central Nervous System Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, cerebrospinal fluid, throat/nasopharyngeal swabs, urine and rectal swabs or stool&#xD;
      samples wil be stored for maximum 10 years.All samples will be de-identified and coded&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient admitted to the hospital and who meets clinical case definition will be&#xD;
        recruited in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical suspicion for Central Nervous system (CNS) infections, OR&#xD;
&#xD;
          2. Any two of the following,&#xD;
&#xD;
               1. Fever or history of fever (≥ 38 °C) during the presenting illness&#xD;
&#xD;
               2. Seizures of new onset&#xD;
&#xD;
               3. Focal neurological deficits&#xD;
&#xD;
               4. Cerebrospinal fluid white cell count pleocytosis (&gt; 4 White blood cells (WBC)/uL)&#xD;
&#xD;
               5. Abnormal neuroimaging suggestive of CNS infection.&#xD;
&#xD;
               6. Abnormal electroencephalogram (EEG) suggestive of CNS infection&#xD;
&#xD;
               7. Depressed or altered level of consciousness, OR&#xD;
&#xD;
          3. No alternative aetiology for acute paralysis identified (e.g stroke, trauma, myopathy&#xD;
             etc)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient or next of kin unwilling to give consent&#xD;
&#xD;
          2. Patients with indwelling ventricular devices such as EVD (external ventricular drain),&#xD;
             VP (ventriculo-peritoneal) shunts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Limin Wijaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>encephalitis</keyword>
  <keyword>viral infections</keyword>
  <keyword>central nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Central Nervous System Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

